The Decay Process of an {\alpha}-configuration Sunspot

The decay of sunspot plays a key role in magnetic flux transportation in solar active regions (ARs). To better understand the physical mechanism of the entire decay process of a sunspot, an {\alpha}-configuration sunspot in AR NOAA 12411 was studied. Based on the continuum intensity images and vector magnetic field data with stray light correction from Solar Dynamics Observatory/Helioseismic and Magnetic Imager, the area, vector magnetic field and magnetic flux in the umbra and penumbra are calculated with time, respectively. Our main results are as follows: (1) The decay curves of the sunspot area in its umbra, penumbra, and whole sunspot take the appearance of Gaussian profiles. The area decay rates of the umbra, penumbra and whole sunspot are -1.56 MSH/day, -12.61 MSH/day and -14.04 MSH/day, respectively; (2) With the decay of the sunspot, the total magnetic field strength and the vertical component of the penumbra increase, and the magnetic field of the penumbra becomes more vertical. Meanwhile, the total magnetic field strength and vertical magnetic field strength for the umbra decrease, and the inclination angle changes slightly with an average value of about 20{\deg}; (3) The magnetic flux decay curves of the sunspot in its umbra, penumbra, and whole sunspot exhibit quadratic patterns, their magnetic flux decay rates of the umbra, penumbra and whole sunspot are -9.84 * 10^19 Mx/day, -1.59 * 10^20 Mx/day and -2.60 * 10^20 Mx/day , respectively. The observation suggests that the penumbra may be transformed into the umbra, resulting in the increase of the average vertical magnetic field strength and the reduction of the inclination angle in the penumbra during the decay of the sunspot

Serological Thymidine Kinase 1 is a Biomarker for Early Detection of Tumours—A Health Screening Study on 35,365 People, Using a Sensitive Chemiluminescent Dot Blot Assay

Serological thymidine kinase 1 (STK1) is a reliable proliferation marker for prognosis, monitoring tumour therapy, and relapse. Here we investigated the use of STK1 in health screening for early detection of pre-malignant and malignant diseases. The investigation was based on 35,365 participants in four independent health screening studies in China between 2005–2011. All participants were clinically examined. The concentration of STK1 was determined by a sensitive chemiluminescent dot blot ECL assay. The ROCvalue of the STK1 assay was 0.96. At a cut-off STK1 value of 2.0 pM, the likelihood (+) value was 236.5, and the sensitivity and the specificity were 0.78 and 0.99, respectively. The relative number of city-dwelling people with elevated STK1 values (≥2.0 pM) was 0.8% (198/26,484), while the corresponding value for the group of oil-field workers was 5.8% (514/8,355). The latter group expressed significantly higher frequency of refractory anaemia, fatty liver, and obesity, compared to the city dwellers, but no cases of breast hyperplasia or prostate hyperplasia. Furthermore, people working in oil drilling/oil transportation showed higher STK1 values and higher frequency of pre-malignancies and benign diseases than people working in the oil-field administration. In the STK1 elevated group of the city-dwelling people, a statistically significantly higher number of people were found to have malignancies, pre-malignancies of all types, moderate/severe type of hyperplasia of breast or prostate, or refractory anaemia, or to be at high risk for hepatitis B, compared to people with normal STK1 values (<2.0 pM). No malignancies were found in the normal STK1 group. In the elevated STK1 group 85.4% showed diseases linked to a higher risk for pre-/early cancerous progression, compared to 52.4% of those with normal STK1 values. Among participants with elevated STK1 values, 8.8% developed new malignancies or progress in their pre-malignancies within 5 to 72 months, compared to 0.2% among people with normal STK1 values. People who showed elevated STK1 values were at about three to five times higher risk to develop malignancies compared to a calculated risk based on a cancer incidence rate of 0.2–0.3%. We conclude that serological TK1 protein concentration is a reliable marker for risk assessment of pre/early cancerous progression

Partial Wave Analysis of J/ψ→γ(K+K−π+π−)J/\psi \to \gamma (K^+K^-\pi^+\pi^-)

BES data on $J/\psi \to \gamma (K^+K^-\pi^+\pi^-)$ are presented. The $K^*\bar K^*$ contribution peaks strongly near threshold. It is fitted with a broad $0^{-+}$ resonance with mass $M = 1800 \pm 100$ MeV, width $\Gamma = 500 \pm 200$ MeV. A broad $2^{++}$ resonance peaking at 2020 MeV is also required with width $\sim 500$ MeV. There is further evidence for a $2^{-+}$ component peaking at 2.55 GeV. The non-$K^*\bar K^*$ contribution is close to phase space; it peaks at 2.6 GeV and is very different from $K^{*}\bar{K^{*}}$.Comment: 15 pages, 6 figures, 1 table, Submitted to PL

Measurement of the Inclusive Charm Cross Section at 4.03 GeV and 4.14 GeV

The cross section for charmed meson production at $\sqrt{s} = 4.03$ and 4.14 GeV has been measured with the Beijing Spectrometer. The measurement was made using 22.3 $pb^{-1}$ of $e^+e^-$ data collected at 4.03 GeV and 1.5 $pb^{-1}$ of $e^+e^-$ data collected at 4.14 GeV. Inclusive observed cross sections for the production of charged and neutral D mesons and momentum spectra are presented. Observed cross sections were radiatively corrected to obtain tree level cross sections. Measurements of the total hadronic cross section are obtained from the charmed meson cross section and an extrapolation of results from below the charm threshold.Comment: 11 pages, 13 figures. The top level tex file is paper.tex. It builds the paper from other tex files in this .tar and the .eps file

Measurement of the Total Cross Section for Hadronic Production by e+e- Annihilation at Energies between 2.6-5 Gev

Using the upgraded Beijing Spectrometer (BESII), we have measured the total cross section for $e^+e^-$ annihilation into hadronic final states at center-of-mass energies of 2.6, 3.2, 3.4, 3.55, 4.6 and 5.0 GeV. Values of $R$, $\sigma(e^+e^-\to {hadrons})/\sigma(e^+e^-\to\mu^+\mu^-)$, are determined.Comment: Submitted to Phys. Rev. Let

Measurement of ψ(2S)\psi(2S) decays to baryon pairs

A sample of 3.95M $\psi(2S)$ decays registered in the BES detector are used to study final states containing pairs of octet and decuplet baryons. We report branching fractions for $\psi(2S)\to p\bar{p}$, $\Lambda\bar{\Lambda}$, $\Sigma^0\bar{\Sigma}{}^0$, $\Xi^-\bar{\Xi}{}^+$, $\Delta^{++}\bar{\Delta}{}^{--}$, $\Sigma^+(1385)\bar{\Sigma}{}^-(1385)$, $\Xi^0(1530)\bar{\Xi}{}^0(1530)$, and $\Omega^-\bar{\Omega}{}^+$. These results are compared to expectations based on the SU(3)-flavor symmetry, factorization, and perturbative QCD.Comment: 22 pages, 21 figures, 4 table

Search for the decay J/ψ→γ+invisibleJ/\psi\to\gamma + \rm {invisible}

We search for $J/\psi$ radiative decays into a weakly interacting neutral particle, namely an invisible particle, using the $J/\psi$ produced through the process $\psi(3686)\to\pi^+\pi^-J/\psi$ in a data sample of $(448.1\pm2.9)\times 10^6$ $\psi(3686)$ decays collected by the BESIII detector at BEPCII. No significant signal is observed. Using a modified frequentist method, upper limits on the branching fractions are set under different assumptions of invisible particle masses up to 1.2 $\mathrm{\ Ge\kern -0.1em V}/c^2$. The upper limit corresponding to an invisible particle with zero mass is 7.0$\times 10^{-7}$ at the 90\% confidence level